Edesa Biotech, Inc. financial data

Symbol
EDSA on Nasdaq
Location
Markham
Fiscal year end
30 September
Latest financial report
10-K - Q3 2025 - 12 Dec 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 892% % 417%
Debt-to-equity 55% % 192%
Return On Equity -65% % 61%
Return On Assets -59% % 44%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8,333,823 shares 140%
Common Stock, Shares, Outstanding 7,141,783 shares 120%
Entity Public Float $13,978,238 USD 26%
Common Stock, Value, Issued $54,515,421 USD 15%
Weighted Average Number of Shares Outstanding, Basic 5,676,708 shares 78%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $3,668,738 USD 27%
General and Administrative Expense $4,242,828 USD 2.7%
Operating Income (Loss) $7,911,566 USD -13%
Nonoperating Income (Expense) $726,843 USD -14%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $1,749,464 USD -4.9%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $7,185,523 USD -16%
Earnings Per Share, Basic -1.27 USD/shares 34%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $10,800,000 USD 980%
Assets, Current $11,512,876 USD 587%
Property, Plant and Equipment, Net $0 USD -100%
Operating Lease, Right-of-Use Asset $0 USD -100%
Assets $13,530,518 USD 255%
Liabilities, Current $1,078,536 USD -41%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $1,832,827 USD -0.48%
Accumulated Other Comprehensive Income (Loss), Net of Tax $165,771 USD 32%
Retained Earnings (Accumulated Deficit) $65,910,974 USD -12%
Stockholders' Equity Attributable to Parent $12,451,982 USD 529%
Liabilities and Equity $13,530,518 USD 255%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,517,203 USD -7.9%
Net Cash Provided by (Used in) Financing Activities $2,071,545 USD 578%
Common Stock, Shares, Issued 7,141,783 shares 120%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $526,182 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,792,172 USD 940%
Deferred Tax Assets, Valuation Allowance $19,733,000 USD 9.2%
Deferred Tax Assets, Gross $19,864,000 USD 9.1%
Operating Lease, Liability $19,867 USD -79%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $7,108,681 USD -15%
Lessee, Operating Lease, Liability, to be Paid $20,019 USD -80%
Property, Plant and Equipment, Gross $52,548 USD 0%
Operating Lease, Liability, Current $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two $19,978 USD -0.1%
Lessee, Operating Lease, Liability, to be Paid, Year One $20,019 USD -75%
Operating Lease, Weighted Average Discount Rate, Percent 0.092 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $152 USD
Preferred Stock, Shares Issued 150 shares
Operating Lease, Payments $17,885 USD -11%
Additional Paid in Capital $14,753,110 USD 8.7%
Amortization of Intangible Assets $30,000 USD 0%
Depreciation, Depletion and Amortization $43,109 USD -4.3%
Deferred Tax Assets, Net of Valuation Allowance $131,000 USD 4%
Share-based Payment Arrangement, Expense $200,000 USD 100%